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Abstract
Background: Mannose-binding lectin (MBL) forms an integral part of the innate immune system.
Persistent, subclinical infections and chronic inflammatory states are hypothesized to contribute to
the pathogenesis of atherosclerosis. MBL gene (MBL2) variants with between 12 to 25% allele
frequency in Caucasian and other populations, result in markedly reduced expression of functional
protein. Prospective epidemiologic studies, including a nested, case-control study from the present
population, have demonstrated the ability of MBL2  genotypes to predict complications of
atherosclerosis,. The genetic control of MBL2 expression is complex and genetic background
effects in specific populations are largely unknown.
Methods: The Strong Heart Study is a longitudinal, cohort study of cardiovascular disease among
American Indians. A subset of individuals genotyped for the above mentioned case-control study
were selected for analysis of circulating MBL levels by double sandwich ELISA method. Mean MBL
levels were compared between genotypic groups and multivariate regression was used to
determine other independent factors influencing MBL2 expression.
Results: Our results confirm the effects of variant structural (B, C, and D) and promoter (H and
Y) alleles that have been seen in other populations. In addition, MBL levels were found to be
positively associated with male gender and hemoglobin A1c levels, but inversely related to
triglyceride levels. Correlation was not found between MBL and other markers of inflammation.
Conclusion: New data is presented concerning the effects of known genetic variants on MBL
levels in an American Indian population, as well as the relationship of MBL2 expression to clinical
and environmental factors, including inflammatory markers.
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Background
Early innate human defenses against microbial invaders
include mannose-binding lectin (MBL), a serum protein,
which acts as a microbial opsonin and initiates activation
of the so-called lectin complement activation pathway.
Deficiencies in innate immunity have been hypothesized
to allow chronic inflammatory states that may contribute
to the pathogenesis of atherosclerosis [1]. Common vari-
ations in the MBL gene (MBL2), between 12 to 25% allele
frequencies in Caucasian and other populations [2], result
in markedly lower levels of circulating MBL [3] and are
associated with both an increased susceptibility to infec-
tions [4] and cardiovascular disease in many [5-8], but not
all studies [9]. An independent association between vari-
ant MBL2 genotypes and coronary artery disease (CAD)
was previously confirmed in the American Indian, Strong
Heart Study (SHS) cohort (OR = 3.2, 95% CI 1.5–7.0, p =
0.004, adjusted for 11 CAD covariates) [10]. On the other
hand, genetypes resulting in high levels of MBL may be
involved in complications related to cardiovascular dis-
ease (CVD). Thus, the role of MBL in cardiovascular dis-
ease appears to be a double-edged sword, due to hitherto
only partially resolved mechanisms [11-13].
Although considerable effort has focused on the genotypic
determination of MBL levels, our understanding of the
role of various promoters and structural genetic variations
remains incomplete. New promoter variants continue to
be identified [14,15] and genetic background effects in
specific populations are largely unknown.
MBL is also known to increase during an acute-phase reac-
tion [16]. Samples collected during follow-up of a subset
of the SHS cohort provide a valuable opportunity to test
the correlation of both genotype and environmental
exposures (e.g. incident CAD and inflammation, as meas-
ured by C-reactive protein (CRP) or fibrinogen) with MBL
levels in this population.
Methods
The previously mentioned SHS case/control study
matched cases and controls on age, gender and recruit-
ment center (Arizona (AZ), Dakotas (DK) and Oklahoma
(OK)). From this group a subset was chosen to include
186 of the controls without regard to genotype and an
additional 51 cases limited to those known to be
homozygous for high expressing "HYA" alleles.
Ascertainment of fatal and nonfatal cardiovascular events
occurring between examinations was accomplished by
medical record review and/or yearly participant contact
[17]. Cases were defined by evidence of definite myocar-
dial infarction (MI), definite coronary artery disease
(CAD) without MI, definite evidence of MI by Minnesota
ECG coding [17], or mortality codes indicating either def-
inite MI, sudden death due to CAD, or definite coronary
heart disease occurring between 5/18/89 and 12/31/99
[18]. Participants with only a diagnosis of possible CAD,
"other CAD", stroke, congestive heart failure, or periph-
eral vascular disease were excluded. Controls were those
individuals without any of the above diagnoses. MBL lev-
els,  MBL2  genotypes and other covariates were deter-
mined from both of these groups. American Diabetes
Association criteria [19] were used to classify participant
diabetic status in table 1. Participants were considered
hypertensive if they were taking anti-hypertensive medica-
tions, had a systolic blood pressure greater than 140 mm
Hg, or a diastolic blood pressure greater than 90 mm Hg.
Determination of MBL levels was done at Rigshositalet in
Copenhagen, Denmark, using a double sandwich ELISA
method as previously described [20].
The MBL2 gene was assessed for the presence of the B
(G54D), C (G57E) or D (R52C) structural variations, and
two promoter polymorphisms, one a G/C transition at -
550 bp (the H/L alleles) [21] and the other, a G/C transi-
tion at -221 (X/Y alleles). These structural variations have
typically been labeled "O" alleles in contrast to the most
common "A" allele. Genotypes were determined by the
oligonucleotide ligation assay as described by Nickerson
and colleagues [22]. Quality control, duplicate, genotyp-
ing was performed by direct DNA sequencing. The struc-
tural variations were assumed to occur on opposing
chromosomes. A number of promoter variants and struc-
tural alleles have been found to be in complete linkage
disequilibrium and genotypes were checked against these
established relationships. [23]. Genotyping was con-
ducted at the University of Pittsburgh, Pittsburgh, Penn-
sylvania.
Composite categories of genotypes predicted to result in
reduced expression of MBL2 similar to previous reports
[3], primarily A_A, A_O, O_O, YA_O, XA_O, HA_O,
LA_O, HYA_O, LYA_O, LXA_O, along with selected spe-
cific haplotypes of adequate prevalence, were used to
guide analysis of genotypic effects on MBL levels. More
inclusive categories used in the previous SHS MBL2 anal-
ysis [10] were also considered. Low expression of MBL2
(LOW_1) was assumed from the presence of an O_O or
LA_O genotype. The LOW_2 category consisted of either
O_O, LA_O or LA_LA genotypes. These risk categories
were compared with reference groups ALL_1 or ALL_2,
consisting of all genotypes not included in either LOW_1
or LOW_2 respectively; or the HIGH category (either
HA_HA or HA_LA). There is ample documentation of the
biologic effect of these various genotypes on basal MBL
levels [23], although unidentified background genetic
influences in unique populations are of interest.BMC Medical Genetics 2009, 10:5 http://www.biomedcentral.com/1471-2350/10/5
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The Chi square statistic was used to evaluate proportions
between groups. Multivariate regression models and com-
parison of means (t test of independent samples) were
used to understand the contribution of the various factors
to MBL2 expression using SPSS version 10.1.0 software.
The distributions of all subgroups in table 2 were exam-
ined and no deviation from the normal distribution was
detected. A nominal p value of 0.05 was used to determine
statistical significance and the Bonferroni correction was
applied in situations of multiple testing.
Approval consistent with the Helsinki Declaration was
obtained from all relevant Institutional Review Boards
and tribes, and all participants gave informed consent.
Results
Table 1 summarizes the characteristics of both cases and
controls. Please note that cases for this study were chosen
on the basis of genotype and since cases and controls were
initially matched for gender, age, and recruitment center,
comparison between aggregated case and control samples
should be interpreted with caution.
There were no significant differences in the prevalence of
O (15.3%) and H (67.2%) alleles in this control sample,
compared with an earlier SHS report [10].
These findings confirm low levels of MBL among individ-
uals with composite genotypic groups (eg O_O, XA_O,
LA_O) [2], as well as those previously associated with
CAD in this SHS population (bolded) [10], as seen in
table 2.
Among controls only, comparing means of composite
genotypes showed highly significant differences (p <
0.001 for all comparisons) between either the HYA_HYA
or HIGH groups and any of the YA_O, HA_O, LA_O,
O_O, LOW1, or LOW2 groups. Figure 1 shows these com-
parisons in the familiar "box-plot" format. The difference
in mean MBL between HYA_HYA and HYA_LYA (unad-





Gender (% Female) 49 52
Age (years) 60.1 58.7
Percentage of participants reporting 100% AI heritage 78 68
Median percent AI heritage among those with less than 100% 65.6 50
Diabetes Mellitus (%) 64.7 39.8
Hypertension (%) 27.5 22.6
Smoking, current (%) 37.3 25.3
Alcohol, current use (%) 41 36
Weight (Kg) 82.9 84.2
BMI (Kg/m2) 29.4 30.4
Hgb A1c (%) 8.2 6.4
LDL Cholesterol (mg/dl) 130.2 119.1
Triglycerides (mg/dl) 198.1 125.5
CRP (mg/dl) 2.99 3.45
Fibrinogen (mg/dl) 319.8 304.7
PAI-1 (mg/dl) 43.3 46.8BMC Medical Genetics 2009, 10:5 http://www.biomedcentral.com/1471-2350/10/5
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justed for multiple testing, p < 0.013), was not significant
considering a Bonferroni correction requiring a p <
0.00365 for a total of 14 pair-wise tests. No significant dif-
ferences were found between MBL means of HYA_LYA
and HYA_LXA or HYA_B and LYA_B (although the last
category was represented by only 8 individuals); other
comparisons attempting to isolate the influence of the H/
L or X/Y promoters were not possible due to small num-
bers of individuals in categories.
Only cases with HYA_HYA genotype were included to
allow adequate numbers to compare with controls of
identical genotype. If the mean MBL levels for case and
control groups of identical genotype are compared (ignor-
ing the previously matched selection of cases and controls
on the basis of age, gender and center), then a crude p
value of 0.812 is obtained.
Multivariate regression analysis was used to investigate
the interplay of various demographic, environmental,
genetic factors on expression of MBL2 within the control
group. A backward selection criterion of F ≥ 0.1 was used
and results are summarized in table 3. Male gender,
hemoglobin A1c levels and self-reported % American
Indian ethnicity are positively correlated with MBL levels;
whereas the converse is true of increasing triglyceride lev-
els and the number of B alleles. Covariates not retained in
this backward selection included: age, diabetes mellitus,
systolic blood pressure, Chlamydia pneumoniae (Cp)
antibody titers, percent body fat, and urinary albumin/
creatinine ratio. Although MBL is an acute phase reactant,
it was not correlated with either inflammatory measures
(CRP, PAI-1, fibrinogen, WBC count) or infectious disease
exposure (Cp titers).
Discussion
Genetic variation in the MBL2 gene has been implicated
in important pathophysiologic processes including sus-
ceptibility to infections [24-26], chronic inflammatory
states and their sequelae [5,6,8,27], and the response to
acute pathology, such as ischemic necrosis [28]. Further
down the pathogenetic chain of events, circulating levels
of this protein are also associated with pathology
[27,29,30]. It is therefore important to fully understand
the genetic and environmental factors governing expres-
sion of this protein. Since MBL is a polymeric protein
comprised of self-assembled trimeric subunits, dominant-
negative structural variants were first recognized to have
marked effects on functional MBL levels. Promoter poly-
morphisms were soon recognized as key determinants of
MBL2 expression and as recently as 2006, new variants
have been identified [3,15,31]. It is likely that additional
influences (eg the endocrine milleu [32,33], variation in
multimeric assembly [34], and epigenetic effects deter-
mined by the "background" population [3] on MBL2
Table 2: MBL levels (μg/L) found in various genotypes and 
genotypic categories.
Haplotype N Min Max Mean SD
Controls
HYA_HYA 76 128 3920 1863.2 854.95
HYA_LYA 34 400 3296 1422.6 826.14
HYA_LXA 21 223 2848 1030.8 709.6
LYA_LYA 2 1040 3024 2032.0 1402.9
LYA_LXA 1 1376.0
LXA_LXA 1 3616.0
HYA_B 27 0 768 168.9 150.7
HYA_C 1 273.0
HYA_D 7 157 1840 696.29 585.9
LYA_B 8 24 233 115.25 84.1
LYA_D 1 448.0
LXA_B 1 0.0
B_B 6 0 0 0.0
YA_O 44 0 1840 251.7 321.9
XA_O 1 0.0
XA_O or O_O 7 0 0 0.0
HA_HA 76 128 3920 1863.2 854.9
HA_LA 55 223 3296 1273.0 800.3
LA_LA 4 1040 3616 2264.0 1250.6
HA_O 35 0 1840 277.3 351.3
LA_O 10 0 448 137.0 137.0
HIGH 131 128 3920 1615.4 879.3
LOW_1 16 0 448 85.6 126.3
LOW_2 20 0 3616 521.3 1029.0
A_A 135 128 3920 1634.7 893.0
Not "A_A" 51 0 1840 217.2 311.1
Cases
HYA_HYA 51 640 5888 1903.6 1043.4BMC Medical Genetics 2009, 10:5 http://www.biomedcentral.com/1471-2350/10/5
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expression and function will continue to be uncovered.
The worldwide high population prevalence of these vari-
ants suggests an apparently ambivalent role of MBL2 in a
number of pathogenetic and homeostatic processes [35-
37].
In this report we have generally confirmed the previously
reported influence of the three main structural variants
and the two most widely investigated promoter variants
(H/L and X/Y). This is of importance due to the demon-
strated association between CVD and these variants in this
particular, non-Caucasian population. Other studies have
reported on the prevalence of MBL2 variants in native
populations of North America [38]; but have not included
information on the expression of MBL2, as in the present
study. Since MBL levels are higher in those with diabetes
(although not seen in this dataset) [27], a correlation with
HgbA1c could be expected. The finding of an association
with lower levels of triglycerides in adjusted analysis is
more difficult to explain, especially since triglyceride lev-
els are often increased in those with diabetes or the meta-
bolic syndrome [39]. Others have also reported increased
MBL levels among males [30]; but no previous analyses of
triglycerides in relation to MBL could be found in the lit-
erature.
Strengths of this study include confirmation of the pre-
sumed link between genotype and expressed protein,
increasing confidence in a possibly causal association
between MBL and cardiovascular disease in this popula-
tion. These results also extend the previously identified
genotype/phenotype correlations to another population
with a unique genetic background. A weakness is the pre-
vious matching structure of the sample and the need to
MBL levels for various genotypes Figure 1
MBL levels for various genotypes. Comparison of mean HIGH and HYA_HYA MBL levels with all other groups is signifi-
cant at p < 0.001. Outliers (between 1.5 and 3 box lengths from upper and lower margin) and extreme values (greater than 3 
box lengths from box margin) are denoted by "o" and "*" respectively.BMC Medical Genetics 2009, 10:5 http://www.biomedcentral.com/1471-2350/10/5
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compare HYA/HYA case genotypes with the same control
genotypes. There were an insufficient number of previ-
ously matched pairs with this genotype to allow a
matched analysis, thus the aggregate comparison between
these two groups needs to be interpreted with caution.
Conclusion
The findings from our study corroborate previous research
that has demonstrated the important effects of genetic var-
iants and the association of metabolic abberations with
MBL levels. Further understanding of MBL2 expression
may improve our ability to understand and disrupt the
pathogenetic mechanisms involved in cardiovascular dis-
ease.
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